Meeting
2012 ASCO Annual Meeting
Phase II trial of sunitinib malate and lomustine in patients with temozolomide refractory recurrent low-grade and anaplastic gliomas.
Authors
Johnny Duerinck
UZ Brussel, Brussels, Belgium
Johnny Duerinck , Stephanie Du Four , An Van Binst , Hendrik Everaert , Alex Michotte , Jean D'haens , Bart Neyns
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
2007-001561-15
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2050)
DOI
10.1200/jco.2012.30.15_suppl.2050
Abstract #
2050
Poster Bd #
13E
Abstract Disclosures
Similar Posters
First Author: Marc C. Chamberlain
Poster
2022 ASCO Annual Meeting
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
First Author: Theodore Willis Laetsch
Poster
2022 ASCO Annual Meeting
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
First Author: Jonathan W. Goldman
Poster
2022 ASCO Annual Meeting
Mebendazole in recurrent glioblastoma: Results of a phase 2 randomized study.
First Author: Nandini Sharrel Menon